trofosfamide has been researched along with Carcinoma, Oat Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Batran, SE; Atmaca, A; Bert, F; Frisch, C; Jäger, D; Jäger, E; Knuth, A; Neumann, A; Orth, J | 1 |
| Halme, M; Isokangas, OP; Joensuu, H; Mäntylä, M; Mattson, K; Pekonen, M; Pyrhönen, S; Ruotsalainen, T; Sarna, S | 1 |
2 trial(s) available for trofosfamide and Carcinoma, Oat Cell
| Article | Year |
|---|---|
Dose escalation study for defining the maximum tolerated dose of continuous oral trofosfamide in pretreated patients with metastatic lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Risk Assessment; Risk Factors | 2004 |
Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer--a feasibility study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Finland; Humans; Ifosfamide; Injections, Subcutaneous; Interferon-alpha; Isotretinoin; Lung Neoplasms; Male; Middle Aged | 2000 |